Depression and antidepressants: molecular and cellular aspects

被引:64
作者
Lanni, Cristina [1 ]
Govoni, Stefano [1 ]
Lucchelli, Adele [1 ]
Boselli, Cinzia [1 ]
机构
[1] Univ Pavia, Ctr Excellence Appl Biol, Dept Expt & Appl Pharmacol, I-27100 Pavia, Italy
关键词
Depression; Neurotransmitter; Neuropeptide; Brain plasticity; Growth factor; CORTICOTROPIN-RELEASING-FACTOR; GAMMA-AMINOBUTYRIC-ACID; PITUITARY-ADRENAL AXIS; V-1B RECEPTOR ANTAGONIST; MAGNETIC-RESONANCE SPECTROSCOPY; DEFICIENT BRATTLEBORO RAT; CENTRAL-NERVOUS-SYSTEM; IN-VIVO MODULATOR; MAJOR DEPRESSION; MOOD DISORDERS;
D O I
10.1007/s00018-009-0055-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Clinical depression is viewed as a physical and psychic disease process having a neuropathological basis, although a clear understanding of its ethiopathology is still missing. The observation that depressive symptoms are influenced by pharmacological manipulation of monoamines led to the hypothesis that depression results from reduced availability or functional deficiency of monoaminergic transmitters in some cerebral regions. However, there are limitations to current monoamine theories related to mood disorders. Recently, a growing body of experimental data has showed that other classes of endogenous compounds, such as neuropeptides and amino acids, may play a significant role in the pathophysiology of affective disorders. With the development of neuroscience, neuronal networks and intracellular pathways have been identified and characterized, describing the existence of the interaction between monoamines and receptors in turn able to modulate the expression of intracellular proteins and neurotrophic factors, suggesting that depression/antidepressants may be intermingled with neurogenesis/neurodegenerative processes.
引用
收藏
页码:2985 / 3008
页数:24
相关论文
共 275 条
  • [111] Serotonergic vulnerability and depression: assumptions, experimental evidence and implications
    Jans, L. A. W.
    Riedel, W. J.
    Markus, C. R.
    Blokland, A.
    [J]. MOLECULAR PSYCHIATRY, 2007, 12 (06) : 522 - 543
  • [112] Jard S, 1987, PROG BRAIN RES <D>, V72, P173
  • [113] Estrogen, serotonin, and mood disturbance: Where is the therapeutic bridge?
    Joffe, H
    Cohen, LS
    [J]. BIOLOGICAL PSYCHIATRY, 1998, 44 (09) : 798 - 811
  • [114] The molecular biology of memory storage: A dialog between genes and synapses
    Kandel, ER
    [J]. BIOSCIENCE REPORTS, 2004, 24 (4-5) : 475 - 522
  • [115] Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets
    Karege, F
    Schwald, M
    Cisse, M
    [J]. NEUROSCIENCE LETTERS, 2002, 328 (03) : 261 - 264
  • [116] KASA K, 1982, BIOL PSYCHIAT, V17, P877
  • [117] Altered behavioural adaptation in mice with neural corticotrophin-releasing factor overexpression
    Kasahara, M.
    Groenink, L.
    Breuer, M.
    Olivier, B.
    Sarnyai, Z.
    [J]. GENES BRAIN AND BEHAVIOR, 2007, 6 (07) : 598 - 607
  • [118] Molecular genetics of bipolar disorder and depression
    Kato, Tadafumi
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2007, 61 (01) : 3 - 19
  • [119] Vasopressin mediates the response of the combined dexamethasone/CRH test in hyper-anxious rats:: Implications for pathogenesis of affective disorders
    Keck, ME
    Wigger, A
    Welt, T
    Müller, MB
    Gesing, A
    Reul, JMHM
    Holsboer, F
    Landgraf, R
    Neumann, ID
    [J]. NEUROPSYCHOPHARMACOLOGY, 2002, 26 (01) : 94 - 105
  • [120] Galanin is a potent in vivo modulator of mesencephalic serotonergic neurotransmission
    Kehr, J
    Yoshitake, T
    Wang, FH
    Razani, H
    Gimenez-Llort, L
    Jansson, A
    Yamaguchi, M
    Ögren, SO
    [J]. NEUROPSYCHOPHARMACOLOGY, 2002, 27 (03) : 341 - 356